Welcome to the Stocktwits Top 25 Newsletter for Week 47 of 2023!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 47:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Standard and Poor's 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+1.27%) outperformed the S&P 500 index (+1.00%).
There was one major change to the list this week.
Microsoft (+2.05%) replaced Expedia Group (+0.03%) on the list.
Check out how the momentum meter has performed vs. the S&P 500 index this year:
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+1.56%) outperformed the Nasdaq 100 index (+0.91%).
There was one major change to the list this week.
Datadog (+3.04%) replaced Marvell Technology (+0.81%) on the list.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+3.79%) outperformed the Russell 2000 index (+0.54%).
There were two major changes to the list this week.
Joining: Aveanna Healthcare (+2.71%) and Dream Finders Homes (+0.45%).
Leaving: Innodata Inc (-24.55%) and Reneo Pharmaceuticals (-7.99%).
🐶🐶🐶
ST Top 25 TOP DAWG OF THE WEEK 🐶
The Top 25 lists’ Top Dawg was Inozyne Pharma, which rallied 20.55%. 📈
The micro-cap clinical-stage biopharmaceutical company didn’t have any specific news related to it this week. It just seems to be rebounding with the broader biotechnology industry, which has had a rough 2023 so far. 🤷
Notably, the Stocktwits community has maintained a neutral to bearish sentiment rating despite the stock’s recent rebound. 🐻
$INZY is up 274.29% YTD.
See Y’all Next Week 🤙
